Activated B cells modulate the maturation of MDSCs via CD36-dependent MHC-II transfer to orchestrate CD4

Zelu Zhang, Shicheng Wang, Junjun Wang, Yichen Yao, Yuankai Hao, Yue Lou, Ping Liu, Lisa X Xu

Abstract read

In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Downregulation of ANKRD22 promotes ovarian cancer cell proliferation by enhancing the immunosuppressive capacity of M-MDSCs.Cancer immunology, immunotherapy : CII · 2026
Article
Multi-omics analysis reveals that Danggui Buxue decoction ameliorates benzene-induced blood deficiency syndrome via the restoration of hematopoietic lineage and remodeling of the immune microenvironment.Chinese medicine · 2026
Article
Myeloid-derived suppressor cells in colorectal cancer: mechanisms of immunosuppression, therapy resistance and therapeutic targeting.Frontiers in cell and developmental biology · 2026
Review
Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma.Theranostics · 2026
Article
CD36 aggravates ferroptosis in NK cells and dampens their anti-fibrotic activity in the liver.Frontiers in immunology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zelu ZhangSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Shicheng WangSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Junjun WangSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Yichen YaoSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Yuankai HaoSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Yue LouSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Ping LiuSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Lisa X XuSchool of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown great success in treating various cancer types. However, the therapeutic efficacy of ICIs remains unsatisfactory because of the immunosuppressive tumor microenvironment. Cryo-thermal therapy (CTT), a novel tumor ablation approach developed by our laboratory, transforms the tumor immunosuppressive environment into an immunostimulatory environment by activating both innate and adaptive immunity. CTT promotes the differentiation of myeloid-derived suppressor cells (MDSCs) into mature dendritic cells and macrophages, activates antigen-presenting cells and natural killer (NK) cells, and induces Th1-dominant CD4

Indexed as

B-LymphocytesCryotherapyHistocompatibility Antigens Class IIMyeloid-Derived Suppressor CellsTh1 CellsAnimalsCD4-Positive T-LymphocytesFemaleImmunotherapyMiceMice, Inbred C57BLTumor MicroenvironmentHistocompatibility Antigens Class IIantitumor immunityB cellsCD36Cryo-thermal therapyMDSCsMHC-II

Identifiers

PMID40959278

DOI10.7150/ijbs.115232

PMCPMC12435582

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.